Premium
A new NF‐κB inhibitor attenuates a T H 1 type immune response in a murine model
Author(s) -
Kabashima Kenji,
Honda Tetsuya,
Nunokawa Youichi,
Miyachi Yoshiki
Publication year - 2004
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2004.10.065
Subject(s) - ovalbumin , immune system , nf κb , nfkb1 , in vivo , in vitro , context (archaeology) , chemistry , ex vivo , immunology , biology , pharmacology , microbiology and biotechnology , cancer research , inflammation , biochemistry , transcription factor , paleontology , gene
Nuclear factor kappa B (NF‐κB) plays a wide variety of pathophysiological roles and modulation of its pathway can be a good novel drug target. Here, we found that our recently synthesized NF‐κB inhibitor attenuated an ovalbumin‐specific delayed‐type hypersensitivity response in vivo and suppressed production of IL‐12 by dendritic cells and T H 1 cytokines by T cells in vitro. These findings suggest that the activation of NF‐κB mounts T H 1 type immune responses, and that this new NF‐κB inhibitor has a therapeutic potential in this context.